Bing Liang Ph.D.

Partner

シリコンバレー + 1.650.687.4168

Connect:

共有

Dr. Bing Liang advises biotechnology and pharmaceutical companies on procuring and protecting intellectual property, with a focus on biologics and diagnostics. She drives and executes global intellectual property strategies for high‑value innovative medicines and has built strategic patent assets covering CARVYKTI®, SKYRIZI®, BOTOX®, PALYNZIQ®, PADCEV®, VENCLEXTA®, NUPLAZID®, POMALYST®, REVLIMID®, and OTEZLA®.

Chambers recognizes Bing as "excellent to work with" and praises her "superlative work," strategic advice, and technical mastery. Clients quoted by Chambers note that her insights and dedication have been "instrumental" in advancing IP strategies and protecting innovation.

Bing prepares and prosecutes patent applications across antibody therapeutics, immuno‑oncology, cell and gene therapies, genome editing, antisense therapeutics, enzyme replacement therapies, stem cells, and genome sequencing.

She advises on patentability, validity, infringement, and freedom to operate and conducts IP due diligence for venture capital and private equity financings, collaborations, and partnering transactions. She has extensive experience with complex cross‑border deals, navigating multijurisdictional intellectual property landscapes and providing strategic insights that support seamless deal execution.

Her practice also includes post‑grant proceedings before the Patent Trial and Appeal Board (PTAB), including inter partes reviews (IPRs).

Bing's representative clients include AbbVie, Merck, BioMarin Pharmaceutical, Bristol Myers Squibb (Celgene), Legend Biotech, and Astellas, as well as start‑ups, established companies, academic institutions, and investment firms.

Before practicing law, Bing earned a Ph.D. in biomedical sciences from the Mount Sinai School of Medicine of New York University, where she researched chromatin remodeling and genome integrity, identifying critical roles for remodeling complexes in DNA damage repair and telomere length maintenance. She brings deep technical experience in biochemistry, molecular biology, genetics, immunology, and cell biology.

担当案件

  • AbbVie collaborates to advance novel bispecific antibody for advanced solid tumorsJones Day advised AbbVie Inc. on an exclusive licensing transaction with RemeGen Co., Ltd. ("RemeGen") relating to a PD-1/VEGF-targeted bispecific antibody, under which RemeGen may receive up to $4.95 billion in milestone payments, plus tiered royalties outside Greater China.
  • AbbVie develops global patent portfolios related to SKYRIZI®Jones Day is representing AbbVie Inc. in the development and prosecution of global patent portfolios related to SKYRIZI®, an interleukin-23 (IL-23) inhibitor for treating inflammatory conditions.
  • AbbVie develops intellectual property strategies related to BOTOX®Jones Day provides strategic intellectual property counseling to AbbVie Inc. regarding its Clostridium botulinum neurotoxin portfolio, including BOTOX® (onabotulinumtoxinA).
  • VelaVigo announces out-licensing deal with Ollin of first-in-class bispecific antibodyJones Day assisted VelaVigo with an intellectual property diligence of VBS-102, a first-in-class bispecific antibody, in connection with its out-licensing to Ollin Biosciences, Inc.
  • Bambusa Therapeutics develops global patent portfolios for bispecific antibodies to treat immunological and inflammatory disordersJones Day represents Bambusa Therapeutics, Inc. in developing global patent portfolios related to various bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders.
  • Merck Animal Health develops global patent portfolios for various veterinary pharmaceuticals and biologics, vaccines, and other health management solutionsJones Day is representing Merck Animal Health, a division of Merck & Co., and the global animal health business of Merck, in developing global patent portfolios related to a wide variety of veterinary pharmaceuticals and biologicals, vaccines, and other health management solutions used to preserve and improve the health, well-being, and performance of animals, including companion animals, ruminants, horses, poultry, and swine.
  • NGM Bio develops global patent portfolio for therapeutic antibodies for the treatment of cancer and tumorsJones Day represents NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for therapeutic antibodies for the treatment of cancer and tumors, including NGM707, a dual ILT2/ILT4 antagonist antibody; NGM831, an ILT3 antagonist antibody; and NGM438, a LAIR1 antagonist antibody.
  • AbbVie partners to develop in-situ CAR-T cell therapiesJones Day advised AbbVie Inc. on IP due diligence in connection with its strategic collaboration and option agreements with Umoja Biopharma, a transaction valued at up to $1.44 billion.
  • Laekna develops global patent portfolios related to various antibody and small molecule drug therapiesJones Day is representing Laekna, Inc. in connection with the development of global patent portfolios related to novel therapeutic antibody and small molecule drug candidates for use in the treatment of various disorders, including cancer, liver fibrosis, and metabolic diseases.
  • METiS Pharmaceuticals develops global patent portfolios related to lipid nanoparticles for mRNA-based gene therapiesJones Day is representing METiS Pharmaceuticals, Inc. in connection with the establishment of global patent portfolios related to lipid nanoparticles (LNP) and uses thereof in various mRNA-based gene therapies.
  • Centrillion Technologies develops patent portfolios related to systems and methods for fabricating high resolution oligonucleotide arraysJones Day is representing Centrillion Technologies, Inc. in counseling and development of global patent portfolios related to systems and methods for fabricating high resolution oligonucleotide arrays, including their applications in sequencing and diagnosis.
  • Exegenesis Bio establishes global patent portfolio related to AAV-based gene therapiesJones Day is representing Exegenesis Bio in connection with the establishment of global patent portfolios related to AAV-based gene therapies for treating central nervous system (CNS), ocular and liver related diseases.
  • Astellas and Agensys prosecute patent portfolios for novel monoclonal antibody and antibody-drug conjugate immunotherapeutics useful for certain cancer treatmentsJones Day represents Astellas Pharma Inc. and its subsidiary Agensys, Inc. in prosecuting their worldwide patent portfolios related to novel monoclonal antibody and antibody-drug conjugate (ADC) immunotherapeutics for use in the treatment of a variety of cancer indications, including PADCEV®, an ADC approved by the FDA in 2019 for the treatment of metastatic bladder cancer.
  • Engage Bio develops global patent portfolio related to mRNA-encoded multi-specific binding moleculesJones Day is representing Engage Biologics, Inc. in connection with the development of a global patent portfolio related to methods of treating disease using mRNAs that encode certain multi-specific binding molecules.
  • Merck develops global patent portfolio related to certain antibodies for treatment of cognitive disordersJones Day is representing Merck & Co., Inc. in the development and prosecution of global patent portfolios related to certain antibodies that are being developed for the treatment and prevention of various cognitive disorders.
  • Merck develops global patent portfolio related to certain bispecific antibodiesJones Day is representing Merck & Co., Inc. in the development and prosecution of a global patent portfolio related to certain bispecific antibodies.
  • Burning Rock establishes global patent portfolio for NGS-related diagnostics and precision oncologyJones Day represents Burning Rock in the development and prosecution of global patent portfolios related to next generation sequencing (NGS) technology for diagnostic and of precision oncology.
  • Nanjing Legend Biotech establishes global patent portfolio for CAR-T therapeuticsJones Day represents Nanjing Legend Biotech Co., Ltd et al in the development and prosecution of global patent portfolios related to chimeric antigen receptor T cell (CAR-T) and other cellular therapeutics, including CARVYKTI ® and other clinical trial candidates.
  • Advanced Cell Diagnostics develops patent portfolios related to assays and systems for in-situ multiplex detection and quantification of RNA molecules for diagnostic applicationsJones Day represented Advanced Cell Diagnostics, Inc. in the development of global patent portfolios related to assays and systems for in-situ multiplex detection and quantification of RNA molecules and applications thereof for diagnosis.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
    •

    OCTOBER 2025 Commentary

    Federal Circuit Clarifies Limits on Patentability of Clinical Study Results-Based Applications

    January 2018 Blog

    Declarations as New Evidence to Overcome § 325(d), PTAB Litigation Blog

    March 2017 Blog

    Including Functional Claim Language Helped Save Pozen’s VIMOVO® Patents, PTAB Litigation Blog

    • April 20, 2019
      The Life Science Patent Landscape and Capital Markets - Updates in China and US, 2019 Chinese Bioscience Association Symposium
    • October 14, 2017
      Opportunities for Biosimilar Companies under the U.S. Legal System, 2017 Chinese Bioscience Association Annual Conference
    • May 8, 2015
      Lecture Presentation, Beijing Foreign Studies University, "Patent Operation in Biotechnological and Pharmaceutical Industries."

    送信する前の注意事項：

    www.jonesday.comに掲載されている情報は、一般的な使用を目的としており、法的アドバイスを目的としたものではありません。このEmailを送信することにより、弁護士を含む専門家・依頼者の関係を構築することを意図するものではなく、このEmailの受領はそのような関係を構築するものではありません。当事務所に送信されたいかなる情報も、業務委託契約を結ばない限り、弁護士等が依頼者に対して守秘義務を負う機密事項として取り扱われることはありません。このEmailの送信者は以上の注意事項の内容を読み、理解したものと判断します。